Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma.

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-08 DOI:10.1016/j.clml.2024.09.005

Rachael Straining, Francine Foss, Molly Schiffer, Kejal Amin, Sonal Agarwal, Iris Isufi, Scott Huntington, Shalin Kothari, Stuart Seropian, Michael Girardi, Tarsheen Sethi

{"title":"Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma.","authors":"Rachael Straining, Francine Foss, Molly Schiffer, Kejal Amin, Sonal Agarwal, Iris Isufi, Scott Huntington, Shalin Kothari, Stuart Seropian, Michael Girardi, Tarsheen Sethi","doi":"10.1016/j.clml.2024.09.005","DOIUrl":null,"url":null,"abstract":"Background: T-cell lymphomas are a heterogeneous group of lymphoid malignancies with poor outcomes. Frontline multiagent chemotherapy options include CHOP (prednisone, vincristine, cyclophosphamide, and doxorubicin), brentuximab-CHP, CHOEP, and EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin).Patients and methods: We report our single institution data for safety and efficacy of EPOCH in 38 patients with aggressive T-cell lymphoma including both peripheral T cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).Results: Eighteen patients received EPOCH as first-line and 21 in the relapsed/refractory (R/R) setting. In 36 evaluable patients, the overall response rate (ORR) was 77% (95% CI, 61%-89%) with 19 (53%) patients achieving complete response (CR) (95% CI, 36%-69%). The ORR in first line and R/R settings were 80% (95% CI, 46%-94%) and 75% (95% CI, 52%-90%), respectively. Response rate was similar in African American versus Caucasian patients but was higher in CD30 negative versus positive patients. Most common grade 3/4 adverse events included cytopenias.Conclusions: Overall, EPOCH was well tolerated with high response rates in first line and R/R setting.","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2024.09.005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: T-cell lymphomas are a heterogeneous group of lymphoid malignancies with poor outcomes. Frontline multiagent chemotherapy options include CHOP (prednisone, vincristine, cyclophosphamide, and doxorubicin), brentuximab-CHP, CHOEP, and EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin).

Patients and methods: We report our single institution data for safety and efficacy of EPOCH in 38 patients with aggressive T-cell lymphoma including both peripheral T cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Results: Eighteen patients received EPOCH as first-line and 21 in the relapsed/refractory (R/R) setting. In 36 evaluable patients, the overall response rate (ORR) was 77% (95% CI, 61%-89%) with 19 (53%) patients achieving complete response (CR) (95% CI, 36%-69%). The ORR in first line and R/R settings were 80% (95% CI, 46%-94%) and 75% (95% CI, 52%-90%), respectively. Response rate was similar in African American versus Caucasian patients but was higher in CD30 negative versus positive patients. Most common grade 3/4 adverse events included cytopenias.

Conclusions: Overall, EPOCH was well tolerated with high response rates in first line and R/R setting.

查看原文本刊更多论文

关于 EPOCH 在 T 细胞淋巴瘤中疗效和安全性的真实世界数据。

背景：T细胞淋巴瘤是一类异质性淋巴恶性肿瘤，治疗效果不佳。一线多药化疗方案包括CHOP（泼尼松、长春新碱、环磷酰胺和多柔比星）、布伦妥昔单抗-CHP、CHOEP和EPOCH（依托泊苷、泼尼松、长春新碱、环磷酰胺和多柔比星）：我们报告了单个机构对38例侵袭性T细胞淋巴瘤（包括外周T细胞淋巴瘤（PTCL）和皮肤T细胞淋巴瘤（CTCL））患者使用EPOCH的安全性和有效性数据：18名患者接受了EPOCH一线治疗，21名患者接受了复发/难治（R/R）治疗。在36例可评估的患者中，总反应率（ORR）为77%（95% CI，61%-89%），其中19例（53%）患者获得完全反应（CR）（95% CI，36%-69%）。一线治疗和R/R治疗的ORR分别为80%（95% CI，46%-94%）和75%（95% CI，52%-90%）。非裔美国人与白种人患者的应答率相似，但CD30阴性与阳性患者的应答率更高。最常见的3/4级不良反应包括细胞减少症：总体而言，EPOCH耐受性良好，在一线和R/R治疗中反应率较高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.